Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10338MR)

This product GTTS-WQ10338MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 10673
UniProt ID Q16552; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10338MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4679MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ5616MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ12708MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ9233MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ6614MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ13755MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ8163MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ9328MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW